Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 331-338

  Yee, Andrew J ^a   Raje, Noopur S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Bone loss; Breast cancer; Denosumab; Prostate cancer; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; GONADORELIN ASSOCIATED PEPTIDE DERIVATIVE; GOSERELIN; LETROZOLE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ARTHRALGIA; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ECZEMA; ENZYME INHIBITION; FLU LIKE SYNDROME; FRACTURE; HUMAN; INFECTION; JAW OSTEONECROSIS; KIDNEY FAILURE; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; PHASE 3 CLINICAL TRIAL (TOPIC); PROPHYLAXIS; PROSTATE CANCER; REVIEW; SIDE EFFECT; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; OSTEOCLASTS; OSTEONECROSIS; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 84872294635     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S14566     Document Type: Review

References (55)

1. Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res. 2010;16(16):4084-4093.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Gralow JR, Biermann JS, Farooki A, etal. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2009;7 Suppl 3:S1-S32; quiz S33-S35.
4. NIH Consensus Development Panel on Osteoporosis. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
5. Cornuz J, Feskanich D, Willett WC, Colditz GA. Smoking, smoking cessation, and risk of hip fracture in women. Am J Med. 1999;106(3): 311-314.
6. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA. 2002;288(18): 2300-2306.
7. Moayyeri A. The association between physical activity and osteoporotic fractures: a review of the evidence and implications for future research. Ann Epidemiol. 2008;18(11):827-835.
8. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
9. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010; 363(21):2027-2035.
10. Black DM, Cummings SR, Karpf DB, etal. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348(9041):1535-1541.
11. Harris ST, Watts NB, Genant HK, etal. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14): 1344-1352.
12. Black DM, Delmas PD, Eastell R, etal. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18): 1809-1822.
13. Rosen LS, Gordon D, Kaminski M, etal. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735-1744.
14. Rosen LS, Gordon D, Tchekmedyian S, etal. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
15. Saad F, Gleason DM, Murray R, etal. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
16. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
17. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677-692.
18. Fizazi K, Lipton A, Mariette X, etal. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-1571.
19. Stopeck AT, Lipton A, Body JJ, etal. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
20. Fizazi K, Carducci M, Smith M, etal. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768): 813-822.
21. Henry DH, Costa L, Goldwasser F, etal. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
22. Adler RA, Gill RS. Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging. 2011;6:119-124.
23. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365-2370.
24. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-1729.
25. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306-3311.
26. Burstein HJ, Prestrud AA, Seidenfeld J, etal. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784-3796.
27. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N EnglJ Med. 2003;348(24):2431-2442.
28. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17): 1299-1309.
29. Ellis GK, Bone HG, Chlebowski R, etal. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
30. Brufsky AM, Bosserman LD, Caradonna RR, etal. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77-85.
31. Eidtmann H, de Boer R, Bundred N, etal. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010; 21(11):2188-2194.
32. Gnant M, Mlineritsch B, Schippinger W, etal. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360(7):679-691.
33. Gnant M, Mlineritsch B, Stoeger H, etal. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631-641.
34. Coleman RE, Marshall H, Cameron D, etal. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15): 1396-1405.
35. Schramek D, Leibbrandt A, Sigl V, etal. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98-102.
36. Jones DH, Nakashima T, Sanchez OH, etal. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084): 692-696.
37. Mohler J, Bahnson RR, Boston B, etal. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2): 162-200.
38. Payne H, Mason M. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer. 2011;105(11):1628-1634.
39. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48(1):88-95.
40. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2): 154-164.
41. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897-7903.
42. Smith MR, Egerdie B, Hernandez Toriz N, etal. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745-755.
43. Smith MR, Saad F, Coleman R, etal. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379(9810):39-46.
44. Task Force. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369-376.
45. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10): 753-761.
46. Saad F, Brown JE, Van Poznak C, etal. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341-1347.
47. Cummings SR, San Martin J, McClung MR, etal. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
48. Papapoulos S, Chapurlat R, Libanati C, etal. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012; 27(3):649-701.
49. Wong BR, Rho J, Arron J, etal. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272(40):25190-25194.
50. Kong YY, Yoshida H, Sarosi I, etal. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
51. Anastasilakis AD, Toulis KA, Goulis DG, etal. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009;41(10): 721-729.
52. Watts NB, Roux C, Modlin JF, etal. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23(1):327-337.
53. Pazianas M, Cooper C, Ebetino FH, Russell RG. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010;6:325-343.
54. Ibrahim A, Scher N, Williams G, etal. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9(7):2394-2399.
55. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676-1679; discussion 1676-1679.